Summary

Despite the use of statins in patients who are dyslipidemic, residual risk of cardiovascular disease remains increased in many individuals [Libby P. J Am Coll Cardiol 2005]. New therapies are therefore needed to enhance the current standard of care for patients with high cardiometabolic risk [Chapman MJ et al. Eur Heart J 2009]. Key opinion leaders discussed the role of other available options for elevating high-density lipoprotein cholesterol.